THC · NYSE · STOCK
Tenet Health (THC) Stock Analysis
$263.93
52W $157.58 – $283.05
58/100
$21.24B
10.1
1.20
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is THC Bullish or Bearish?
Bullish.
Innellis AI committee rates Tenet Health (THC) Buy with a composite score of 58/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +16.51 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -3.49 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 66.2% yoy. Risk Analyst remains cautious — high leverage (debt-to-equity 3.12) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- P/E of 9.4 is inexpensive for the broad market — Value
- ROE of 50.6% shows genuine earnings power backing the valuation — Value
- EPS growing 66.2% YoY — Growth
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Price-to-book of 4.1x prices in significant intangible value — Value
- Debt-to-equity of 3.12 adds balance-sheet risk to the value case — Value
- High leverage (debt-to-equity 3.12) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
58/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 42%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ P/E of 9.4 is inexpensive for the broad market
− Price-to-book of 4.1x prices in significant intangible value
Growth Analyst
bullish
72
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 66.2% YoY
Technical Analyst
bullish
69
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 3.12) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score strengthened from 55.1 to 58.5.
- New bullish signals: 3 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
- Analyst(s) changed stance: Technical Analyst.
Analyst-level changes:
- Technical Analyst: stance neutral->bullish; score 48->69 (+20); +3 bullish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
63.7
Neutral
MACD Histogram
0.252
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$186.46
Resistance
$282.25
Bollinger %B
0.79
Inside Bands
Price vs Moving Averages
EMA 9
$259.95
Above
EMA 21
$259.87
Above
EMA 50
$253.44
Above
EMA 200
$220.56
Above
Fundamental Analysis
Valuation
83
Growth
94
Profitability
54
Financial Health
25
Cash Flow
70
Valuation
P/E Ratio
10.1×
P/B Ratio
4.73×
PEG Ratio
0.15
Dividend Yield
0.00%
52W High
$283.05
52W Low
$157.58
Quality & Growth
ROE
3334.1%
ROA
474.1%
Gross Margin
2686.6%
Operating Margin
1679.8%
Revenue Growth YoY
—
Debt / Equity
2.84
AI Fundamental Assessment
P/E ratio of 10.1 (inexpensive relative to a 15-40x range); Price-to-book of 4.7x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 33.3%; Return on assets of 4.7%; Net margin of 10.3%; Gross margin of 26.9%; Current ratio of 1.41 (tight short-term liquidity); Debt-to-equity of 2.84; Free cash flow per share is positive (36.19); Most recent quarter beat estimates by 43.6%; 4 consecutive earnings beats; EPS growth accelerating (+2.6% -> +27.0% QoQ); Analyst estimates rising over recent quarters
Get the Full THC Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →